Conflict of interest: none declared.
Experimental dermatology ● Concise Report
Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo
Version of Record online: 20 JUN 2013
© 2013 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 39, Issue 1, pages 54–57, January 2014
How to Cite
Miniati, A., Weng, Z., Zhang, B., Therianou, A., Vasiadi, M., Nicolaidou, E., Stratigos, A. J., Antoniou, C. and Theoharides, T. C. (2014), Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clinical and Experimental Dermatology, 39: 54–57. doi: 10.1111/ced.12164
- Issue online: 17 DEC 2013
- Version of Record online: 20 JUN 2013
- Manuscript Accepted: 4 FEB 2013
- National Institutes of Health. Grant Number: AR47652
Vitiligo is a disorder of depigmentation, for which the pathogenesis is as yet unclear. Interleukin (IL)-8 (CXCL8) is a key inflammatory chemokine. We investigated the regulation of IL-8 production in human melanocytes, and the IL-8 serum levels and skin gene expression in patients with vitiligo and in controls. Cultured melanocytes were stimulated for 24 h with tumour necrosis factor (TNF) 100 ng/mL and IL-1β 10 ng/mL, with or without pretreatment with luteolin 50 μmol/L for 30 min, and IL-8 release was measured by ELISA. Serum cytokines were measured by a microbead array. Skin biopsies were taken from healthy subjects (n = 14) as well as from marginal lesional and nonlesional skin from patients with vitiligo (n = 15). IL-8 gene expression was evaluated by quantitative real time PCR. Both TNF and IL-1β stimulated significant IL-8 release (P < 0.01) from melanocytes, whereas pretreatment with luteolin significantly inhibited this effect (P < 0.01). IL-8 gene expression was significantly increased in vitiligo compared with control skin (P < 0.05). IL-8 may be involved in vitiligo inflammation. Inhibition by luteolin of IL-8 release could be useful for vitiligo therapy.